Marginal Zone Lymphoma

B-cell pulmonary lymphoma without extra-pulmonary disease (primary pulmonary lymphoma) remains a rare entity, often arising from mucosa-associated lymphoid tissue, presenting with non-specific symptoms (cough, dyspnoea) and imaging (nodules <5 cm or areas of consolidation on CT), and diagnosed by an adequate biopsy.Our patient's course demonstrates early, pre-clinical changes: anaemia of inflammation and monocytosis, which became more severe as symptoms developed and imaging abnormalities progressed, and was associated with marked acute-phase response (for example, substantially increased ferritin levels), increased globulins and hyponatraemia due to the syndrome of inappropriate antidiuretic hormone secretion.In patients with unexplained anaemia of inflammatory disease, occult pulmonary lymphoma should be considered in the differential diagnosis.

The factors influencing RMALT development, such as the presence of HEVs, C-X-C motif chemokine ligand 13 expression, and RMALT-containing cell proliferation, were also explored. Overall, this study revealed the detailed attributes of RMALTs, their immune cell composition, and their determinants in male and female mice, providing insights into the sex-specific characteristics of the rectal mucosal immune system.

Zandelisib showed favourable efficacy and tolerability in Japanese patients with relapsed or refractory indolent non-Hodgkin B-cell lymphoma. This unique dosing schedule may maintain efficacy while mitigating the safety issues observed with other PI3Kδ inhibitors (ClinicalTrials.gov number, NCT04533581).

P2, N=159, Completed, Kite, A Gilead Company | Active, not recruiting --> Completed

P2, N=30, Active, not recruiting, Sidney Kimmel Cancer Center at Thomas Jefferson University | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Sep 2025

P1, N=30, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2024 --> Jun 2025

P2, N=9, Terminated, University of Washington | Trial completion date: Apr 2026 --> Aug 2024 | Active, not recruiting --> Terminated; Closed per SRC Low Accrual Policy.

P2, N=9, Terminated, University of Washington | Trial completion date: Apr 2026 --> Aug 2024 | Active, not recruiting --> Terminated; Closed per SRC Low Accrual Policy.

In vivo, silencing of EsMALT1 rendered crabs susceptible to bacterial infection and impaired their bacterial clearance. In conclusion, EsMALT1 promotes both humoral and cellular immunity in E. sinensis, making it essential for the induction of antibacterial immune responses.

P=N/A, N=22, Terminated, University of Ulm | N=56 --> 22 | Trial completion date: Apr 2029 --> Dec 2024 | Recruiting --> Terminated | Trial primary completion date: Apr 2029 --> Dec 2024; Due to slow recruitment caused by the COVID-19 pandemic and associated retrictions and the authorization of zanubrutinib. Additionally, many competing trials promising higher efficacy have been started in the meantime.

Additionally, we confirm that the altered bcl6 expression observed in relapsed EMZL cases is independent of BCL6 gene rearrangement, as demonstrated by fluorescence in situ hybridization analysis. Relevant literature was reviewed and summarized to enhance the understanding of this phenomenon, particularly for pathologists.

P1, N=492, Recruiting, Nurix Therapeutics, Inc. | N=292 --> 492 | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Dec 2025 --> Jan 2027

The first-line treatment of HCL has recently changed and immunochemotherapy combining cladribine plus rituximab has become the gold standard. In relapsed or refractory forms, other treatments should be discussed in a multidisciplinary consultation meeting and combine BRAF inhibitors with anti-CD20 antibodies, BTK inhibitors or Bcl-2 inhibitors. The choices should be discussed according to the patient's profile but also their biological profile.

The revised classification of the EBV-positive lymphoproliferative disorders in children is discussed. This review will focus on novel findings, areas of special interest, and diagnostic challenges in pediatric lymphomas.

This research investigates how miR-21-Exo influences chemotherapy-induced POI using an experimental model where KGN cells are exposed to cisplatin...Further studies in a rat model demonstrated the therapeutic potential and safety of miR-21-Exo. Overall, our findings highlight a novel strategy for addressing chemotherapy-induced POI by modulating MALT1 and the NF-κB pathway, offering significant therapeutic implications.

Partial positivity for CD23 is a common feature of LPL in the BM. Together with other clinical and histological parameters, CD23 expression supports the differential diagnosis between LPL and MZL.

Key concepts in the diagnosis and their clinical implications are emphasized. Controversies and challenges are also discussed.

In the group of five patients with indolent lymphoma and CD20 expression loss, three patients (60%) had concurrent transformation to high-grade lymphoma. This study, which reinforces the importance of repeating a biopsy at relapse before implementing CD20-directed therapy, is particularly relevant given the widespread use of rituximab along with the emerging significance of CD20-targeted bispecific antibodies in the management of B-cell lymphomas.

Amulirafusp alfa showed favorable safety profile and preliminary efficacy in patients with r/r B-NHL, meriting further investigation. Trial registration NCT05805943.

P2, N=33, Not yet recruiting, Gottfried von Keudell, MD PhD | Initiation date: Sep 2024 --> Jan 2025

P2, N=22, Recruiting, Lazaros Lekakis | N=40 --> 22

To the best of our knowledge, this is the first reported case of AITL with TCR::MYC rearrangement. This condition could be associated with refractoriness to chemotherapy and aggressive clinical course with systemic infiltration that included the intestine.

P1/2, N=621, Recruiting, BeiGene | N=466 --> 621

Among the upregulated variants, TNFSF13B (BAFF)-206 acts as a transcription factor and is reported to enhance BAFF production in autoimmune diseases and cancer. Altogether, these findings implicate the NLRC5-BAFF signalling axis in Helicobacter-induced B cell MALT lymphoma, highlighting BAFF inhibition as a potential therapeutic approach.

The six-year follow-up showed that concurrent and independent orbital MALT lymphoma and axillary reactive lymphoid hyperplasia, likely due to unicentric Castleman disease, were both stable. The present case illustrates how important it is to make pathological diagnoses in different anatomical lesions after the initial diagnosis of Castleman disease.

P1/2, N=60, Recruiting, Enterome | Trial completion date: Sep 2029 --> May 2032 | Trial primary completion date: Jun 2025 --> May 2026

Consequently, she was treated with rituximab for PMZL, with plans to address the adenocarcinoma through stereotactic body radiation therapy (SBRT)...While a direct correlation between chronic inflammation, frequent infectious pathogens, and the development of PMZL has yet to be established, a known association exists between EMZL and pathogens such as Helicobacter pylori in gastric involvement and Chlamydia psittaci in ocular adnexa. This report highlights the difficulties in obtaining a diagnosis for PMZL and examines the various mechanisms that may have contributed to this unusual finding.

No abstract available

P1/2, N=11, Completed, Mayo Clinic | Active, not recruiting --> Completed

Whole body gene expression analyses uncovered waves of igmh, cd4-2b, and cd8a expression that recapitulate the cellular seeding sequence of O-NALT by specific lymphocyte subsets. Our results indicate that 1) O-NALT formation results from a specific sequence of lymphocyte subset colonization pioneered by CD8α+ T cells and 2) the presence of the full O-NALT structure at 1400 DD may mark this timepoint as the earliest developmental stage at which mucosal vaccines can induce long lasting, specific immune responses.

P=N/A, N=500, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting

P=N/A, N=100, Not yet recruiting, International Extranodal Lymphoma Study Group (IELSG)

P1, N=18, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2026 --> Feb 2025 | Trial primary completion date: Oct 2026 --> Feb 2025

While robust, BIOMED-2 primer PCR can show dominant IgK peaks, which may be misinterpreted. This presents a diagnostic pitfall in the workup of pediatric tonsils that community pathologists must consider.

P1, N=100, Recruiting, Byondis B.V. | Trial primary completion date: Oct 2024 --> Oct 2025

P1, N=18, Not yet recruiting, GenomeFrontier Therapeutics TW Co., Ltd.

P2, N=35, Recruiting, Izidore Lossos, MD | Not yet recruiting --> Recruiting

P1/2, N=53, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Phase classification: P1b/2 --> P1/2 | Trial primary completion date: May 2024 --> Jan 2024

P3, N=168, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Mar 2024 --> Mar 2025

Our findings indicated that CagA and NFATc1 cooperatively participate in the lymphomagenesis of HPE-responsive gastric MALT lymphoma.

P1, N=316, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2024 --> Dec 2025

P1/2, N=54, Completed, Incyte Corporation | Active, not recruiting --> Completed